PeproTech TRAIL-R2 (DR5) (soluble) Polyclonal Antibody, PeproTech®, Invitrogen™

Descripción

AA Sequence of recombinant protein: MESALITQQD LAPQQRVAPQ QKRSSPSEGL CPPGHHISED GRDCISCKYG QDYSTHWNDL LFCLRCTRCD SGEVELSPCT TTRNTVCQCE EGTFREEDSP EMCRKCRTGC PRGMVKVGDC TPWSDIECVH KES. Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human sTRAIL Receptor-2. Anti-Human sTRAIL Receptor-2-specific antibody was purified by affinity chromatography employing an immobilized Human sTRAIL Receptor-2 matrix. Sandwich ELISA: To detect Human sTRAIL Receptor-2 by sandwich ELISA (using 100 μL/well antibody solution) a concentration of 0.5-2.0 μg/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with PeproTech Biotinylated Anti-Human sTRAIL Receptor-2 (500-P299Bt) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human sTRAIL Receptor-2. Western Blot: To detect hsTRAIL Receptor-2 by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 μg/mL. Used in conjunction with compatible secondary reagents the detection limit for Recombinant hsTRAIL Receptor-2 is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.

DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.